following an abbreviated submission:
icatibant acetate (Firazyr®) is accepted for use within NHSScotland.
Indication under review: symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.
SMC has previously accepted icatibant acetate for use in adults.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of icatibant. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHSScotland.
Download detailed advice46KB (PDF)
- Medicine name:
- icatibant (Firazyr)
- SMC ID:
- Symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency).
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Respiratory system
- Submission type
- Date advice published:
- 07 May 2018